Brepoels L - Search Results

1

PET and PET/CT for response evaluation in lymphoma: current practice and developments.

Brepoels L, Stroobants S, Verhoef G. Brepoels L, et al. Leuk Lymphoma. 2007 Feb;48(2):270-82. doi: 10.1080/10428190601078118. Leuk Lymphoma. 2007. PMID: 17325886 Review.

2

Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.

Brepoels L, Stroobants S, Vandenberghe P, Spaepen K, Dupont P, Nuyts J, Bormans G, Mortelmans L, Verhoef G, De Wolf-Peeters C. Brepoels L, et al. J Nucl Med. 2007 Mar;48(3):390-7. J Nucl Med. 2007. PMID: 17332616 Free article.

3

Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Brepoels L, et al. Leuk Lymphoma. 2007 Aug;48(8):1522-30. doi: 10.1080/10428190701474365. Leuk Lymphoma. 2007. PMID: 17701583

4

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Brepoels L, et al. Leuk Lymphoma. 2007 Aug;48(8):1539-47. doi: 10.1080/10428190701422414. Leuk Lymphoma. 2007. PMID: 17701585

5

Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?

Brepoels L, Stroobants S. Brepoels L, et al. Hematol Oncol Clin North Am. 2007 Oct;21(5):855-69. doi: 10.1016/j.hoc.2007.07.003. Hematol Oncol Clin North Am. 2007. PMID: 17908624 Review.

6

Positron emission tomography in mantle cell lymphoma.

Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, Mortelmans L, Verhoef G, De Wolf-Peeters C. Brepoels L, et al. Leuk Lymphoma. 2008 Sep;49(9):1693-701. doi: 10.1080/10428190802216707. Leuk Lymphoma. 2008. PMID: 18798104 Clinical Trial.

7

PET scanning and prognosis in Hodgkin's lymphoma.

Brepoels L, Stroobants S. Brepoels L, et al. Curr Opin Oncol. 2008 Sep;20(5):509-16. doi: 10.1097/CCO.0b013e32830b88d3. Curr Opin Oncol. 2008. PMID: 19106652 Review.

8

(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.

Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. Brepoels L, et al. J Nucl Med. 2009 Jul;50(7):1102-9. doi: 10.2967/jnumed.109.062208. Epub 2009 Jun 12. J Nucl Med. 2009. PMID: 19525456 Free article.

9

Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET.

Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, Mortelmans L, Mottaghy FM. Brepoels L, et al. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1688-95. doi: 10.1007/s00259-010-1479-0. Epub 2010 May 12. Eur J Nucl Med Mol Imaging. 2010. PMID: 20461370 Free article.

10

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.

Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, Verhoef GE, Chundru S, Douglas-Nikitin V, Oliver Wong CY, Brepoels LM. Karam M, et al. Among authors: brepoels lm. Nucl Med Commun. 2009 Oct;30(10):770-8. doi: 10.1097/MNM.0b013e32832e0c13. Nucl Med Commun. 2009. PMID: 19657307

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters